Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic “off the shelf” bone cell therapy for the treatment of severe osteoporosis.
The trial supplants a previous Phase IIA trial of PREOB® autologous therapy for the same indication. Company leadership noted that ALLOB presents advantages in dosing, logistics and scalability, which may make it an easier product to commercialize for use by a larger patient population.
PREOB remains in pivotal Phase IIB/III clinical studies for osteonecrosis and non-union fracture indications. The Phase II ALLOB trial is expected to commence in early 2017.
Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic “off the shelf” bone cell therapy for the treatment of severe osteoporosis.
The trial supplants a previous Phase IIA trial of PREOB® autologous therapy for the same indication. Company leadership noted that ALLOB presents advantages in dosing, logistics and scalability,...
Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic “off the shelf” bone cell therapy for the treatment of severe osteoporosis.
The trial supplants a previous Phase IIA trial of PREOB® autologous therapy for the same indication. Company leadership noted that ALLOB presents advantages in dosing, logistics and scalability, which may make it an easier product to commercialize for use by a larger patient population.
PREOB remains in pivotal Phase IIB/III clinical studies for osteonecrosis and non-union fracture indications. The Phase II ALLOB trial is expected to commence in early 2017.
Copy to clipboard 
